Biomaterial-Mediated Genetic Reprogramming of Merkel Cell Carcinoma and Melanoma Leads to Targeted Cancer Cell Killing <i>In Vitro</i> and <i>In Vivo</i>.

"The authors declare the following competing financial interest(s): S.Y.T. and J.J.G. are co-founders and managers of OncoSwitch Therapeutics, LLC. S.Y.T., J.C.S., J.J.G., and K.M.L. are co-inventors on related patents awarded and pending."

"J.C.S. thanks the Dermatology Foundation and the Dermatopathology Career Development Award for supporting and advancing his career. The graphical abstract was generated in BioRender. The authors thank Dr. Nathan Archer for advice on immune characterization assays. This work was funded by the National Institutes of Health (R37CA246699, P41EB028239, and R01CA228133) and the State of Maryland’s Technology Development Corporation (TEDCO Maryland Innovation Initiative). The Johns Hopkins Oncology Tissue Services core is funded by the National Institutes of Health (P30CA006973)."